By otakuyassine3@gmail.com 
Proficio Capital Partners LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 142,139 shares of the company’s stock, valued at approximately $31,936,000. Proficio Capital Partners LLC owned about 0.07% of Cencora at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the company. M&T Bank Corp boosted its holdings in Cencora by 4.3% during the 4th quarter. M&T Bank Corp now owns 15,592 shares of the company’s stock worth $3,503,000 after acquiring an additional 636 shares during the last quarter. Assetmark Inc. boosted its holdings in Cencora by 1,165.7% during the 4th quarter. Assetmark Inc. now owns 32,097 shares of the company’s stock worth $7,212,000 after acquiring an additional 29,561 shares during the last quarter. Triad Wealth Partners LLC purchased a new position in Cencora during the 4th quarter worth $463,000. Cypress Capital Group boosted its holdings in shares of Cencora by 0.4% in the 4th quarter. Cypress Capital Group now owns 20,356 shares of the company’s stock worth $4,574,000 after buying an additional 87 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Cencora by 25.2% in the 4th quarter. Victory Capital Management Inc. now owns 255,425 shares of the company’s stock worth $57,389,000 after buying an additional 51,345 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
COR has been the topic of a number of research analyst reports. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday. Evercore ISI boosted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $280.20.
View Our Latest Research Report on Cencora
Cencora Trading Up 0.8 %
Shares of Cencora stock opened at $258.09 on Friday. The stock’s 50-day simple moving average is $247.59 and its 200 day simple moving average is $239.09. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $263.70. The stock has a market capitalization of $50.05 billion, a P/E ratio of 36.71, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.
Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.85%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.
Insider Activity
In other news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,648 shares of company stock worth $3,382,462 over the last ninety days. Company insiders own 10.80% of the company’s stock.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cencora and related companies with MarketBeat.com’s FREE daily email newsletter.